Drostanolone Propionate
Fast-acting DHT-derived compound with 2.5-day half-life and no aromatization.
Drostanolone Propionate
Drostanolone Propionate is a sterile oil-based injectable preparation of drostanolone esterified with propionic acid, presented at 100 milligrams per millilitre in a 10 mL multiple dose vial. Drostanolone is a derivative of dihydrotestosterone and is valued for a profile that is entirely free of oestrogenic activity.
Structural Profile
Drostanolone is 2-alpha-methyl-dihydrotestosterone. The 2-alpha methyl group protects the molecule against inactivation by 3-alpha-hydroxysteroid dehydrogenase, substantially increasing its anabolic potency relative to unmodified dihydrotestosterone. With the propionate ester at the 17-beta position the molecular formula is C23H36O3, molar mass 360.53 g/mol, registered under CAS number 521-12-0.
Esterification and Release
The three-carbon propionate ester gives a short depot phase, with rapid onset and rapid clearance. A short injection interval is therefore required, which in exchange permits precise control of serum concentration.
Pharmacokinetic Profile
The elimination half-life is approximately 2.5 days. Serum concentrations peak within 24 to 36 hours of administration and decline over the following days. The urinary detection window extends to approximately 3 weeks, among the shortest of the injectable preparations.
Mechanism of Action
Drostanolone binds the cytoplasmic androgen receptor and the activated complex regulates transcription at androgen response elements, promoting structural protein synthesis in skeletal muscle. As a dihydrotestosterone derivative the molecule is not a substrate for aromatase, so no conversion to oestradiol occurs at any dose. Drostanolone additionally exhibits weak anti-oestrogenic activity through competition at the aromatase enzyme.
Manufacturing and Sterility
Each production lot is released against the complete pharmaceutical testing protocol: HPLC identity confirmation and purity analysis with a specification of not less than 98 percent, verification of concentration against label claim within 5 percent, sterility testing in accordance with USP <71>, bacterial endotoxin quantification by LAL assay below 0.25 EU/mL, and particulate matter inspection in accordance with USP <788>. A Certificate of Analysis is issued for every lot.
Quality Assurance
Every batch of Drostanolone Propionate produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.
Authentication
Each unit of Drostanolone Propionate carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.